The proposed project aims to explore whether international polygenic and molecular risk scores derived from genomics, proteomics, metabolomics, or integrated multi-omics approaches can reliably predict disease risk and early progression in Swedish cohorts, where feasibility has not yet been assessed. The effectiveness of these scores will be evaluated for common cardiometabolic diseases, cancers, and psychiatric disorders, including type 1 and type 2 diabetes, coronary artery disease, chronic kidney disease, stroke, venous thromboembolism, obesity, hypertension, hypercholesterolemia, atrial fibrillation, depression, asthma, and cancers of the breast, prostate, lung, colon, skin, ovary, and endometrium. The potential of polygenic and molecular risk scores to inform early interventions and treatment strategies will also be explored.